Indivior’s INDV-2000 Study Completion: A Potential Game-Changer for Opioid Use Disorder

Indivior PLC (INDV) announced an update on their ongoing clinical study.

Indivior PLC recently completed a Phase II clinical study titled ‘A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of INDV-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder.’ The study aimed to evaluate the safety and efficacy of INDV-2000, a novel treatment for individuals with moderate to severe Opioid Use Disorder (OUD), and to determine the appropriate dosing for future trials.

The intervention being tested is INDV-2000, a highly potent and selective OX1R antagonist, designed to help individuals with OUD transition from opioid-based treatments to non-opioid alternatives. The study also included a placebo group for comparison.

This study was interventional, randomized, and used a parallel assignment model. It was triple-masked, meaning that the participants, care providers, and investigators were unaware of the treatment assignments. The primary purpose was to assess treatment efficacy.

The study began on April 22, 2024, and was completed on December 15, 2025. These dates are crucial as they mark the timeline for data collection and analysis, which can impact the timing of regulatory submissions and market entry.

The successful completion of this study could positively impact Indivior’s stock performance by enhancing investor confidence in the company’s pipeline. As the opioid crisis continues to be a significant public health issue, effective treatments like INDV-2000 could position Indivior favorably against competitors in the addiction treatment market.

The study is now completed, with further details available on the ClinicalTrials portal.

To learn more about INDV’s potential, visit the Indivior PLC drug pipeline page.